A study to find out whether maraviroc given once daily is as effective as Truvada given once daily in treating HIV-infected patients never previously treated with maraviroc.
- Registry ID
- EUCTR2010-021785-30
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- ViiV Healthcare UK Limited
- Start date
- 2011-11-21
- Completion date
- 2014-01-28
- Last update
- 2026-08-16
Conditions
Summary
To assess whether maraviroc (SelzentryTM, Celsentri®) administered once daily (QD) is non inferior to a reference regimen of emtricitabine/tenofovir administered QD each in combination with darunavir/ritonavir in the treatment of antiretroviral naïve HIV 1 infected subjects as measured by the proportion of subjects with HIV 1 RNA below the limits of assay detection (<50 copies of HIV 1 RNA per milliliter of plasma) at Week 48.
Locations
- , , UK
- , , Sweden
- , , Portugal
- , , Poland
- , , Austria
- , , Denmark
- , , Spain
- , , Belgium
- , , Germany
- , , Finland
- , , Netherlands
- , , Hungary
- , , Italy
View on source registry